Reversal of cocaine withdrawal-induced anxiety by ondansetron, buspirone and propranolol

Behavioural Brain Research

Volumn 231, Issue 1, 2012, Pages 116-123

  Citó, Maria do Carmo de Oliveira ^a   Da Silva, Francisca Charliane Carlos ^a   Silva, Maria Izabel Gomes ^a   Moura, Brinell Arcanjo ^a   Macêdo, Danielle Silveira ^a   Woods, David John ^b   Fonteles, Marta Maria de França ^a   Vasconcelos, Silvânia Maria Mendes de ^a   Sousa, Francisca Cléa Florenço de ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Anxiolytic drugs; Cocaine; Cocaine withdrawal induced anxiety

Indexed keywords

BUSPIRONE; COCAINE; ONDANSETRON; PROPRANOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG EFFECT; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAT; WITHDRAWAL SYNDROME;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BUSPIRONE; COCAINE; MALE; MOTOR ACTIVITY; ONDANSETRON; PROPRANOLOL; RATS; RATS, WISTAR; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84859066935     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.01.056     Document Type: Article

References (55)

1. Soares B.G., Lima M.S., Reisser A.A., Farrel M. Dopamine agonists for cocaine dependence. Cochrane Database Syst Rev 2003, 2.
2. Sofuoglo M., Dudish-Poulsen S., Poling J., Mooney M., Hatsukami D.K. The effect of individual cocaine withdrawal symptoms on outcomes in cocaine users. Addict Behav 2005, 30:1125-1134.
3. Reith M.E., Li M.Y., Yan Q.S. Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers. Psychopharmacology(Berl) 1997, 134(3):309-317.
4. Pollock D.A., Holmgreen P., Lui K.J., Kirk M.L. Discrepancies in the reported frequency of cocaine-related deaths, United States, 1983 through 1988. JAMA 1991, 266:2233-2237.
5. Dworking S.I., Co C., Smith J.E. Rat brain neurotransmitter turnover rates altered with during withdrawal from chronic cocaine administration. Brain Res 1995, 682:116-126.
6. Wang Z., Ordway Z.A., Woolverton W. Effects of cocaine on monoamine as measured ex vivo. Neurosci Lett 2007, 413:191-195.
7. Gordon M.K., Rosen J.B. Lasting effect of repeated cocaine administration on acoustic and fear-potentiated startle in rats. Psychopharmacology (Berl) 1999, 144:1-7.
8. Erb S., Kayyali H., Romero K. A study of the lasting effects of cocaine pre-exposure on anxiety-like behaviors under baseline conditions and in response to central injections of corticotropin-releasing factor. Pharmacol Biochem Behav 2006, 85(1):206-213.
9. Santucci A.C., Madeira E. Anxiogenesis in adult rats treated chronically cocaine during adolescence: effects of extended abstinence and O-8-DPAT treatment. Brain Res Bull 2008, 76:402-411.
10. Ettenberg A., Bernardi R.E. Anxiolytic-like actions of buspirone in a runway model of intravenous cocaine self-administration. Pharmacol Biochem Behav 2006, 85:393-399.
11. Gawin F.H. Desipramine facilitation of initial cocaine abstinence. Arch Gen Psychiatry 1989, 46:117-121.
12. Markou A., Hauger R.L., Koob G.F. Desmethylimipramine attenuates cocaine withdrawal in rats. Psychopharmacology (Berl) 1992, 109:305-331.
13. Paine T.A., Jackman S.L., Olmstead M.C. Cocaine-induced anxiety: alleviation by diazepam, but not buspirone, dimenhydrinate or diphenhydramine. Behav Pharmacol 2002, 13:511-523.
14. Lister R.G. Ethologicaly based animal models of anxiety disorders. Pharmacol Ther 1973, 46:321-340.
15. Archer J. Tests for emotionality in rats and mice. A review. Anim Behav 1973, 21:205-235.
16. Malgozarta F., Faron-Górecka A., Kusmider M., Golda A., Malgozarta F., Dziedzicka-Wasylewska M. Alterations in BDNF and trkb mRNAs following acute or sensitizing cocaine treatments and withdrawal. Brain Res 2006, 1071:218-225.
17. Muller C.P., Carey R.J., Wilkisz M., Schwenzner S., Jocham G., Huston J.P., et al. Acute anxiolytic effects of cocaine: the role of test latency and activity phase. Pharmacol Biochem Behav 2008, 89:218-226.
18. Ettenberg A., Bernardi R.E. Effects of buspirone on the immediate positive and delayed negative properties of intravenous cocaine as measured in the conditioned place preference test. Pharmacol Biochem Behav 2007, 87:171-178.
19. Sarnyai Z., Biró E., Gardi J., Vecsernyes M., Julesz J., Telegdy G. Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. Brain Res 1995, 675:89-97.
20. Santucci A.C., Rabidou D., Rosario A. Residual learning deficit and anxiogenesis in rats treated chronically with cocaine during adolescence. Soc Neurosci 2008, 659.
21. Anthony J.C., Tien A.Y., Petronis K.R. Epidemiologic evidence on cocaine use and panic attacks. Am J Epidemiol 1989, 129:543-549.
22. Estroff T.W., Schwartz R.H., Hoffmann N.G. Adolescent cocaine abuse. Addictive potential, behavioral and psychiatric effects. Clin Pediatr 1989, 28:550-555.
23. Hayase T., Yamamoto Y., Yamamoto K. Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands. Behav Pharmacol 2005, 16:395-404.
24. Borowski T.B., Kokkinidis L. The effects of cocaine, amphetamine, and the dopamine D1 receptor agonist SKF 38393 on fear extinction as measured with potentiated startle: implications for psychomotor stimulant psychosis. Behav Neurosci 1998, 112:952-965.
25. Rogerio R., Takahashi R.N. Anxiogenic action of acute but not repeated cocaine administration in handling-habituated mice in the plus-maze test. Braz J Med Biol Res 1992, 25:713-716.
26. Rogerio R., Takahashi R.N. Anxiogenic properties of cocaine in the rat evaluated with the elevated plus-maze. Pharmacol Biochem Behav 1992, 43:631-633.
27. Blanchard D.C., Blanchard R.J. Cocaine potentiates defensive behaviors related to fear and anxiety. Neurosci Biobehav Rev 1999, 23:981-991.
28. Darmani N.A., Hadfield M.G., Carter W.H., Martin B.R. Acute and chronic effects of cocaine on isolation-induced aggression in mice. Psychopharmacology (Berl) 1990, 102:37-40.
29. Costall B., Kelly M.E., Naylor R.J., Onaivi E.S. The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol Biochem Behav 1989, 33:197-203.
30. Gawin F.H. Cocaine addiction: psychology and neurophysiology. Science 1991, 251:1580-1586.
31. Perrine S.A., Sheikh I.S., Nwaneshiudu C.A., Schroeder J.A., Unterwald E.M. Withdrawal from cronic administration of cocaine decreases delta opioid receptor signaling and increases anxiety and depression like behaviors in the rat. Neuropharmacology 2008, 54:355-364.
32. Sofuoglu M., Dudish-Poulsen S., Brown S.B., Hatsukami D.K. Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. Drug Alcohol Depend 2003, 69:273-282.
33. De Souza Silva M.A., Mello E.L., Müller C.P., Jocham G., Maior R.S., Huston J.P., et al. The tachykinin NK3 receptor antagonist SR142801 blocks the behavioral effects of cocaine in marmoset monkeys. Eur J Pharmacol 2006, 536:269-278.
34. Freeman K.V., Verendeev A., Riley A.L. Noradrenergic antagonism enhances the conditioned aversive effects of cocaine. Pharmacol Biochem Behav 2008, 88:523-532.
35. Mantsch J.R., Weyer A., Vranjkovic A., Beyer C.E., Baker D.A., Creta H. Involvement of noradrenergic neurotransmission in the stress but not cocaine induced reinstatement of reinstatement of extinguished cocaine induced conditioned place preference in mice: role for beta-2 adrenergic receptors. Neuropsychopharmacology 2010, 35(11):2165-2178.
36. Kampman K.M., Volpicelli J.R., Mulvaney F., Alterman A.I., Cornish J., Gariti P., et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend 2001, 63(1):69-78.
37. Kampman K.M., Dackis C., Lynch K.G., Pettinati H., Tirado C., Gariti P., et al. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug Alcohol Depend 2006, 85:129-137.
38. Harris G.C., Aston-Jones G. β-Adrenergic antagonists attenuate withdrawal anxiety in cocaine and morphine-dependent rats. Psychopharmacology (Berl) 1993, 113:131-136.
39. Abrams J.K., Johnson P.L., Hay-Schmidt A., Mikkelsen J.D., Shekhar A., Lowry C.A. Serotonergic systems associated with arousal and vigilance behaviors following administration of anxiogenic drugs. Neuroscience 2005, 133(4):983-997.
40. 3 antagonist, in a novel animal model. Methods Find Exp Clin Pharmacol 1997, 19:107-111.
41. Lane J.D., Pickering C.L., Hooper M.L., Fagan K., Tyers M.B., Emmett-Oglesby M.W. Failure of ondansetron to block the discrimanative or reinforcing stimulus effects of cocaine in the rat. Drug Alcohol Depend 1992, 30(2):151-162.
42. Davidson C., Lazarus C., Lee T.H., Ellinwood T.H. Ondansetron, given during the acute cocaine withdrawal, attenuates oral cocaine self-administration. Eur J Pharmacol 2004, 503:99-102.
43. Cole J.C., Rodgers R.J. Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol. Psychopharmacology 2005, 114(2):288-296.
44. 1A ligand BP 554 mimics the anxiolitic activity of buspirone, gepirone, and ipsapirone in the plus maze in rats. Braz J Pharmacol 1992, 105:130.
45. Fulton B., Brogden R.N. Buspirone, an updated review of its clinical pharmacology and therapeutic applications. CNS Drugs 1997, 7:68-88.
46. Bond A.J., Wingrove J., Baylis M., Dalton J. Buspirone decreases physiological reactivity to unconditioned and conditioned aversive stimuli. Psychopharmacology 2003, 165:291-295.
47. Sanger D.J. Effects of buspirone and elated compounds on suppressed operant responding in rats. J Pharmacol Exp Ther 1990, 254:420-427.
48. Martin J.R., Moreau J.L., Jenck F., Cumin R. Acute and chronic administration of buspirone fails to yield anxiolytic-like effects in mouse operant punishment paradigm. Pharmacol Biochem Behav 1993, 46:905-910.
49. 1A agonists by shock intensity. Pharmacol Biochem Behav 1993, 46:569-573.
50. 3 receptor agonist 1-(m-chlorophenyl)-biguanide interacts with the dopamine transporter in rat brain synaptosomes. Eur J Pharmacol 1995, 290(2):157-162.
51. Bloomstone J.A. The drug-abusing parturient. Int Anesthesiol Clin 2002, 40:137-150.
52. Silva M.I.G., Cito M.C.O., Amaral J.F., Aquino Neto M.R., Moura B.A., Vasconcelos P.F., et al. Behavioral and neurochemical evaluation in rats withdrawal from repeated cocaine treatment and exposed to the forced swimming and open field rats. J Theor Exp Pharmacol 2008, 1:62-71.
53. Cunningham K.A., Paris J.M., Goeders N.E. Serotonin neurotransmission in cocaine sensitization. Ann N Y Acad Sci 1992, 654:117-127.
54. 3 receptor antagonist, and cocaine. Psychopharmacology 1997, 130:159-165.
55. 3 receptor antagonist administered during withdrawal from intermittent and continuous cocaine. Psychopharmacology 1998, 135:263-269.